336 related articles for article (PubMed ID: 28902952)
1. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
[No Abstract] [Full Text] [Related]
2. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
[No Abstract] [Full Text] [Related]
3. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report.
Thorlacius L; Theut Riis P; Jemec GBE
Br J Dermatol; 2018 Jul; 179(1):182-185. PubMed ID: 28654150
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
[No Abstract] [Full Text] [Related]
5. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
7. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
[No Abstract] [Full Text] [Related]
8. Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
Hotz C; Sbidian E; Ingen-Housz-Oro S; Chosidow O; Wolkenstein P
Acta Derm Venereol; 2019 Nov; 99(12):1170-1171. PubMed ID: 31314122
[No Abstract] [Full Text] [Related]
9. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
10. Management of recalcitrant hidradenitis suppurativa with ustekinumab.
Sharon VR; Garcia MS; Bagheri S; Goodarzi H; Yang C; Ono Y; Maverakis E
Acta Derm Venereol; 2012 May; 92(3):320-1. PubMed ID: 22101775
[No Abstract] [Full Text] [Related]
11. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
Yao Y; Thomsen SF
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692
[TBL] [Abstract][Full Text] [Related]
12. Two diseases one remedy? Systemic amyloidosis secondary to hidradenitis suppurativa: Treatment with infliximab.
Özer İ; Karaçin C; Adışen E; Güz G; Ali Gürer M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27862787
[TBL] [Abstract][Full Text] [Related]
13. Association and management of Crohn's disease plus hidradenitis suppurativa.
dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
[No Abstract] [Full Text] [Related]
14. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.
Brunasso AM; Massone C
Eur J Dermatol; 2010; 20(5):644-6. PubMed ID: 20615818
[No Abstract] [Full Text] [Related]
15. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
16. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
Ingram JR; Burton T
Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
[No Abstract] [Full Text] [Related]
17. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance.
Frew JW; Marzano AV; Wolk K; Join-Lambert O; Alavi A; Lowes MA; Piguet V
J Invest Dermatol; 2021 Feb; 141(2):316-324.e2. PubMed ID: 32919760
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.
Sotiriou E; Apalla Z; Vakirlis E; Ioannides D
Eur J Dermatol; 2009; 19(2):180-1. PubMed ID: 19153066
[No Abstract] [Full Text] [Related]
19. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab.
Montes-Romero JA; Callejas-Rubio JL; Sánchez-Cano D; González-Martínez FJ; Navas-Parejo A; Ortego-Centeno N
Eur J Intern Med; 2008 Oct; 19(6):e32-3. PubMed ID: 18848164
[No Abstract] [Full Text] [Related]
20. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.
Houriet C; Seyed Jafari SM; Thomi R; Schlapbach C; Borradori L; Yawalkar N; Hunger RE
JAMA Dermatol; 2017 Nov; 153(11):1195-1197. PubMed ID: 28854317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
